Skip to main content
NIH funding notice RFA-DK-16-004

Development of New Technologies and Bioengineering Solutions for the Advancement of Cell Replacement Therapies for Type 1 Diabetes (R43/R44)

Closed on June 28, 2016.

Posted
November 19, 2015
Close date
June 28, 2016
Activity codes
Not stated on the notice page
Institutes taking part
Not stated on the notice page

Read the notice on Grants.gov · NIH Guide page

The notices it replaced

Its page was not saved, so the notices it replaced are not known.

Who won it before

4 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $899,194 in first-year total cost, median $224,924.

Most frequent study sections

  1. Special Emphasis Panel[ZDK1 GRB-2 (J3)]4

Most frequent institutions

  1. GINER, INC.1
  2. PROFUSA, INC.1
  3. PROPAGENIX, INC.1
  4. SYLVATICA BIOTECH, INC.1
Competing awards under RFA-DK-16-004 and the notices it replaced
FYProjectPIsInstitutionFirst-year costStudy section
2017Enhancement of Conditional Reprogramming Technology for Production of Functional Human Beta-Cells1R43DK113539-01POLLOK, BRIAN ANDREWPROPAGENIX, INC., MD$225,000ZDK1
2017Pressure Management Technologies for Oxygenation of Implanted Insulin Secreting Cells1R43DK113536-01STONE, SIMON G.GINER, INC., MA$224,936ZDK1
2017Wireless Technology for Long-Term Non-Invasive O2 Sensing within Cell Encapsulation Devices in Vivo1R43DK113519-01PAPAS, KLEARCHOS KWISNIEWSKI, NATALIE ANNPROFUSA, INC., CA$224,911ZDK1
2017Nature-inspired methods for long-term banking of endocrine cells within encapsulation devices1R43DK113537-01PAPAS, KLEARCHOS KTAYLOR, MICHAEL JOHNSYLVATICA BIOTECH, INC., SC$224,347ZDK1

Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-12-0.1.3. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.

ScienceDex for faculty

Your academic CV and NIH biosketch

Make your CV in your school's format and your NIH biosketch from it, then download both as Word files.

RFA-DK-16-004: Development of New Technologies and Bioengineering Solutions for the Advancement of Cell Replacement Therapies for Type 1 Diabetes (R43/R44) | ScienceDex | ConductScience